01 / Guideline numbers
What the guidelines say about this number
Normal vs optimal
Lab reference intervals for ApoB vary and are typically population-based, not outcome-based. The numbers above are a risk enhancer and optional goals from the 2026 guideline plus a US population median, and the goals differ by risk category. If your report prints a single "normal" cutoff, ask which body it comes from.
02 / Why it matters
What the number tells you
In 2024 the National Lipid Association wrote that "Specific apoB thresholds have not been suggested in U.S. guidelines and recommendations". That changed with the 2026 ACC/AHA dyslipidemia guideline, published online March 13, 2026, which the NLA co-authored and endorsed. Its table of risk enhancers lists apoB of 120 mg/dL or higher in one row with an LDL-C persistently 160 to 189 mg/dL or a non-HDL-C of 190 to 219. Its goal figure sets apoB goals of under 90, under 70 and under 55 mg/dL, tied to triglycerides of 150 to 499, diabetes, or clinical atherosclerotic cardiovascular disease (ASCVD), and its treatment algorithms for diabetes, high triglycerides and clinical ASCVD label the apoB goals optional. ACC's September 2026 feature on the guideline describes "an optional Apo-B goal in conditions associated with increased remnant lipoproteins". Two one-page corrections to the guideline were published on June 22 and September 8, 2026, and we could not read them, so the numbers here are as printed in ACC's reproduction of the guideline's tables and figures, read October 19, 2026.
- Population context (NLA 2024, NHANES 2005 to 2016, untreated US adults): the median ApoB is 90 mg/dL, the 90th percentile 125, the 95th percentile 137.
03 / In practice
Testing and what moves it
When it is tested
- Not part of a standard lipid panel; ordered separately or as part of an advanced lipid test.
- The AHA's release on the 2026 guideline says apoB may be used to assess residual risk and guide treatment in people with cardiovascular-kidney-metabolic syndrome, type 2 diabetes, high triglycerides or known cardiovascular disease who have reached their LDL-C and non-HDL-C goals.
What raises it
- The same drivers as LDL-C plus insulin resistance and high triglycerides, which raise the number of small dense particles without a matching rise in LDL-C.
What lowers it
- Statins, ezetimibe and PCSK9 inhibitors lower ApoB alongside LDL-C; weight loss and better glycemic control lower the triglyceride-rich fraction.
04 / Related
Read next
Frequently asked questions
Is ApoB better than LDL cholesterol?
ApoB counts atherogenic particles; LDL-C measures the cholesterol they carry. The NLA 2024 consensus supports using ApoB to refine risk and guide intensity, especially when triglycerides are high or LDL-C looks discordant with overall risk. US guidelines have not replaced LDL-C with ApoB: ACC's July 2026 article on the 2026 guideline says "LDL-C remains the mainstay of cholesterol screening and target".
What ApoB should I aim for?
It depends on your group. The 2026 ACC/AHA guideline sets apoB goals of under 90 mg/dL at a 10-year PREVENT-ASCVD risk under 10% with triglycerides of 150 to 499, or with diabetes without risk factors; under 70 at a risk of 10% or more with those triglycerides, or with diabetes and risk factors; and under 55 for clinical ASCVD at very high risk. Its treatment algorithms for diabetes, high triglycerides and clinical ASCVD label these apoB goals optional. The US median of 90 mg/dL in untreated adults is a population statistic, not a goal.
2 documents set the numbers on this page. The oldest was published in 2024, the newest in 2026.
- 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia, Table 13 (risk enhancers), as reproduced in ACC's Lipid Manager
- National Lipid Association Expert Clinical Consensus on apolipoprotein B (2024)
We last re-read these sources on . How we verify.